In addition to the case description, we provide a focused review of the literature on RET fusions as an emerging resistance pathway in EGFR-mutant NSCLC and discuss evolving therapeutic strategies to address this mechanism of treatment failure. This evidence concerns the gene RET and non-small cell lung carcinoma.